TABLE 3.
Antiproliferative and NO-production inhibition activity of Eugenia pyriformis leaves essential oil.
| Antiproliferative activity (GI50 values, μg mL−1) | ||||
|---|---|---|---|---|
| Essential oil | SI | Ellipticine | SI | |
| Breast adenocarcinoma (MCF-7) | 291.51 ± 19.56aB | 1.29 | 0.91 ± 0.04aA | 3.54 |
| Lung carcinoma (NCI-H460) | 328.00 ± 15.55abB | 1.15 | 1.03 ± 0.09aA | 3.13 |
| Cervical carcinoma (HeLa) | 337.25 ± 18.24bB | 1.12 | 1.91 ± 0.06aA | 1.70 |
| Hepatocellular carcinoma (HepG2) | 270.86 ± 27.02aB | 1.40 | 1.14 ± 0.21aA | 2.82 |
| Porcine liver primary cells (PLP2) | 378.50 ± 9.65aB | - | 3.22 ± 0.67aA | - |
| Murine macrophage cells (RAW 246.7) | ||||
| Essential oil | Dexamethasone | |||
| Toxic effects (GI50 values, μg mL−1) | >400 | |||
| NO-production inhibition (EC50, μg mL−1) | 92.04 ± 8.24b | 15.70 ± 1.10a | ||
Values are expressed as arithmetic mean ± standard deviation. GI₅₀, essential oil concentration responsible for 50% cell proliferation inhibition; SI, selectivity index (GI50 μg mL−1 non-tumor cell line/GI50 μg mL−1 tumor cell line). EC₅₀, effective concentration providing 50% inhibition of nitric oxide (NO) production. The means followed by the same uppercase letters in the lines and the same lowercase letters in the column do not differ significantly by Tukey’s HSD test (p ≤ 0.05).